Endocrine-resistant metastatic breast tumor, glioblastoma, refractory acute myeloid leukemia, … to beat incurable cancers, Diaccurate explores the new frontiers of oncology in search of daring novel therapeutic approaches able to save lives. Now in the clinic, the French biotech is currently developing 3 proprietary therapeutics with novel mechanisms of action across several development programs:
- DIACC3010, an optimized S...
Endocrine-resistant metastatic breast tumor, glioblastoma, refractory acute myeloid leukemia, … to beat incurable cancers, Diaccurate explores the new frontiers of oncology in search of daring novel therapeutic approaches able to save lives. Now in the clinic, the French biotech is currently developing 3 proprietary therapeutics with novel mechanisms of action across several development programs:
- DIACC3010, an optimized S6 Kinase inhibitor, highly selective oral antitumoral agent that crosses the blood-brain barrier
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.